CBLL is a commercial-stage medical technology company specializing in the diagnosis and management of serious neurological conditions. It has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform that combines portable hardware and artificial intelligence-powered algorithms to enable rapid diagnosis and continuous monitoring of patients. CBLL focuses on improving patient outcomes and hospital economics by addressing unmet needs in acute care settings.
- Product Revenue - Offers the Ceribell System, including portable hardware such as a disposable headband and battery-operated recorder, designed for rapid deployment and ease of use in acute care settings.
- Subscription Revenue - Provides access to proprietary AI-powered algorithms and a web-based portal for real-time EEG data monitoring and remote neurologist access.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Xingjuan (Jane) Chao ExecutiveBoard | Chief Executive Officer | Xingjuan (Jane) Chao is the CEO of CBLL since October 2015 and co-founder of the company. She has also served as President since July 2016 and as a Board Member since August 2015. | View Report → | |
Joseph S. Manni Executive | Chief Revenue Officer | Joseph S. Manni is the Chief Revenue Officer at CBLL since April 1, 2025. He previously served as Senior Vice President of Sales starting in April 2024, and he brings over 25 years of experience in healthcare sales and leadership. | ||
Raymond Woo Executive | Chief Technology Officer | Raymond Woo, Ph.D., has served as the Chief Technology Officer at CBLL since February 2017, after serving as Vice President of Engineering from June 2016 to February 2017. | ||
Scott Blumberg Executive | Chief Financial Officer | Scott Blumberg has been serving as Chief Financial Officer at CBLL since April 2020. He has extensive experience in finance, having previously held roles such as Managing Advisor at Venture Forward Advisory Services, Director of Business Development at IDEV Technologies, and Analyst at Bay City Capital. |
- In Q1, you beat revenue consensus by about $1 million and raised your full-year guidance by roughly $2 million; can you break down which specific account acquisition or usage initiatives are driving this improved visibility and how they will translate into sequential revenue growth?
- With the impending potential of 145% tariffs on imports from China in Q4, what concrete mitigation strategies (such as reshoring or vendor negotiations) do you plan to implement, and what is the timeline for these actions to offset potential margin pressure?
- Gross margins remain strong at 88% in Q1 despite tariff pressures, but given your cost-intensive investments in sales, marketing, and R&D, how do you plan to maintain or improve these margins while balancing increased operating expenses and stock-based compensation?
- Your operating expenses grew 55% YoY due to heightened investments and IPO-related costs; can you specify which areas of expense will drive future efficiencies and when you expect these investments to begin producing notable impacts on your path to cash flow breakeven?
- Regarding the pediatric Clarity product, which is not factored into 2025 guidance, what are the key milestones and performance metrics you will monitor during the limited commercial release to ensure a smooth transition to a full launch and revenue contribution in subsequent years?
Research analysts who have asked questions during Ceribell earnings calls.
Joshua Jennings
TD Cowen
7 questions for CBLL
Stephanie Piazzola
Bank of America
6 questions for CBLL
Robert Marcus
JPMorgan Chase & Co.
5 questions for CBLL
William Plovanic
Canaccord Genuity
4 questions for CBLL
Macauley Kilbane
William Blair & Company
3 questions for CBLL
Jon Young
Canaccord Genuity Group Inc.
2 questions for CBLL
Lilia-Celine Lozada
JPMorgan Chase & Co.
2 questions for CBLL
Bill Plovanic
Canaccord Genuity
1 question for CBLL
Brandon Vazquez
William Blair & Company, L.L.C.
1 question for CBLL
Marie Thibault
BTIG
1 question for CBLL
Travis Steed
Bank of America
1 question for CBLL
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Natus Medical Incorporated | The company is one of the primary providers of conventional EEG systems in the United States, which are used in the majority of hospitals for outpatient epilepsy diagnosis and are often deployed in the acute care setting for patients at risk of seizure. They also face competition from companies designing rapid EEG systems or systems specifically for acute care settings. |
This company is another primary provider of conventional EEG systems in the United States, similar to Natus Medical Incorporated. They also compete in the market for rapid EEG systems or systems specifically designed for acute care settings. |
Recent press releases and 8-K filings for CBLL.
- CeriBell reported strong financial performance for its last quarter, with $21.2 million in revenue, 38% year-to-year growth, and an 88% gross margin, operating in 584 US accounts.
- The company targets a $2 billion total addressable market (TAM) in the US for seizure detection, currently 3% penetrated, and is expanding its neural monitoring platform to pediatric and neonatal populations, as well as new indications like delirium and stroke, aiming to make EEG a new vital sign.
- CeriBell is derisking its supply chain by establishing a new manufacturing site in Vietnam, which will be operational by the end of the current quarter (Q3), while maintaining a dominant market position through superior products, its proprietary AI algorithm, and extensive clinical evidence.
- Key investment areas include growing commercial infrastructure, significant R&D for new indications, and generating further clinical evidence to drive adoption and establish EEG as a standard of care.
- CeriBell, Inc. announced on July 7, 2025, that it filed complaints against Natus Medical Incorporated and its subsidiaries, alleging patent infringement and unfair competition.
- The complaints were filed with the U.S. International Trade Commission (USITC) and the U.S. District Court in Delaware.
- Ceribell asserts that Natus is infringing six of its patents related to important features of its EEG headband and electrode design.
- Ceribell has requested the USITC to investigate its claims and issue an exclusion order to bar the importation of any infringing Natus products into the United States.